Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Sigma Healthcare Ltd (ASX: SIG) shares surged 9% on Thursday and are the most actively traded stock on their first day of trading post-merger with Chemist Warehouse.

The Sigma share price rose by 9.4% to an intraday high of $3.02 per share today.

The stock has since retraced a little to be trading at $2.94, up 6.52%.

The scheme of arrangement between the two companies was officially implemented yesterday, and about 4.3 billion unescrowed new Sigma shares began trading today.

A group of people in a corporate setting do a collective high five.

Image source: Getty Images

First day of trading for repackaged Sigma Healthcare shares

At the time of writing, almost 128.5 million Sigma shares have been traded on Thursday, making it the most traded stock of the day, according to CommSec data.

Some of this trading is likely Chemist Warehouse franchisees offloading their holdings.

This blockbuster merger sure has excited the market, and today's share price leap indicates continued optimism for the future.

The Sigma share price has soared since the proposal was announced on 11 December 2023.

The excitement surrounding the deal prompted many investors to buy Sigma shares.

The new demand resulted in Sigma becoming the No. 1 ASX 200 healthcare share for price growth last year.

Sigma shareholders were thrilled with the proposed deal and voted overwhelmingly in favour of it last month.

Today, Sigma is the ASX 200's second-largest healthcare stock with a market capitalisation of $31.84 billion.

Shares held under escrow

Sigma now officially holds all of the ordinary shares in CW Group Holdings Limited, and Chemist Warehouse is now a wholly owned subsidiary of Sigma Healthcare.

A total of 9.9 billion shares were issued as part of the consideration for Sigma's purchase.

However, approximately 5.6 billion remain under escrow.

Chemist Warehouse shareholders who were entitled to receive consideration got just under 45 cents in cash and just over 6.3 new Sigma shares for each Chemist Warehouse share held.

Sigma estimated the market value of those new shares at $2.83 per share.

The 5.6 billion new Sigma shares under escrow were issued in three separate parcels to Chemist Warehouse co-founders Jack Gance and Sam Gance, and CEO Mario Verrocchi.

Sigma said the trio was "committed to the long-term value creation opportunities available to Sigma" post-merger and had therefore agreed to voluntary escrow arrangements.

Subject to certain exceptions, they cannot sell any of their escrowed shares during the First Escrow Period, defined as between now and the earlier of 31 August or the close of trading on the day that Sigma releases its financial results for the period ending 30 June this year.

They cannot sell 90% of their escrowed shares between the end of the First Escrow Period and the earlier of either 31 August 2026 or the close of trading on the day that Sigma releases its financial results for the period ending 30 June 2026.

Jack Gance and Mario Verrocchi, along with Chemist Warehouse's chief property officer Damien Gance, and chief people officer Danielle Di Pilla, have been appointed to the Sigma board.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

This drug developer could have huge upside, brokers say

Gains of more than 100% are not off the cards apparently.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Four ASX healthcare stocks which are looking cheap

These companies could be just what the doctor ordered.

Read more »

Two health workers taking a break.
Healthcare Shares

Bell Potter is tipping this exciting ASX healthcare stock to rise 80%

An important clinical trial announcement is good news for this healthcare stock.

Read more »

A woman looks nonplussed as she holds up a handful of Australian $50 notes.
Healthcare Shares

Is this one of the best ASX 200 stocks money can buy?

High margins, strong growth, and global expansion have helped this ASX company stand out to me.

Read more »

A man clenches his fists in excitement as gold coins fall from the sky.
Healthcare Shares

Why is this ASX 200 share charging 7% higher today?

This stock is making its shareholders smile on Tuesday. Let's find out why.

Read more »

A patient in a hospital bed is reassured by a doctor.
Healthcare Shares

Here's why Ramsay Health Care shares have been demolishing the stock market

Investors are warming to the healthcare stock’s earnings recovery.

Read more »

Three businesspeople leap high with the CBD in the background.
Healthcare Shares

Telix shares jump 14% on big news

Let's see what this radiopharmaceuticals company has announced this morning.

Read more »

Rede arrow on a stock market chart going down.
52-Week Lows

Why the CSL share price just hit a 9-year low

CSL shares slump to levels last seen in December 2017.

Read more »